Prot# CC-5013-CLL-001: A Multi-Center, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Two Lenalidomide Dose Regimens in Subjects with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date5/11/079/1/11

Funding

  • Celgene Corporation (CC-5013-CLL-001)